S&P 500   3,638.35 (+0.24%)
DOW   29,910.37 (+0.13%)
QQQ   299.01 (+0.92%)
AAPL   116.59 (+0.48%)
MSFT   215.23 (+0.64%)
FB   277.81 (+0.81%)
GOOGL   1,787.02 (+1.30%)
AMZN   3,195.34 (+0.32%)
TSLA   585.76 (+2.05%)
NVDA   530.45 (+0.20%)
BABA   276.48 (-0.45%)
CGC   29.00 (+7.93%)
GE   10.40 (-0.95%)
MU   64.23 (+1.26%)
AMD   87.19 (+0.55%)
T   29.03 (+0.14%)
NIO   54.00 (+0.58%)
F   9.09 (+0.11%)
ACB   10.47 (+20.21%)
NFLX   491.36 (+1.31%)
GILD   60.03 (+0.89%)
BA   216.50 (-0.51%)
DIS   147.13 (-1.31%)
S&P 500   3,638.35 (+0.24%)
DOW   29,910.37 (+0.13%)
QQQ   299.01 (+0.92%)
AAPL   116.59 (+0.48%)
MSFT   215.23 (+0.64%)
FB   277.81 (+0.81%)
GOOGL   1,787.02 (+1.30%)
AMZN   3,195.34 (+0.32%)
TSLA   585.76 (+2.05%)
NVDA   530.45 (+0.20%)
BABA   276.48 (-0.45%)
CGC   29.00 (+7.93%)
GE   10.40 (-0.95%)
MU   64.23 (+1.26%)
AMD   87.19 (+0.55%)
T   29.03 (+0.14%)
NIO   54.00 (+0.58%)
F   9.09 (+0.11%)
ACB   10.47 (+20.21%)
NFLX   491.36 (+1.31%)
GILD   60.03 (+0.89%)
BA   216.50 (-0.51%)
DIS   147.13 (-1.31%)
S&P 500   3,638.35 (+0.24%)
DOW   29,910.37 (+0.13%)
QQQ   299.01 (+0.92%)
AAPL   116.59 (+0.48%)
MSFT   215.23 (+0.64%)
FB   277.81 (+0.81%)
GOOGL   1,787.02 (+1.30%)
AMZN   3,195.34 (+0.32%)
TSLA   585.76 (+2.05%)
NVDA   530.45 (+0.20%)
BABA   276.48 (-0.45%)
CGC   29.00 (+7.93%)
GE   10.40 (-0.95%)
MU   64.23 (+1.26%)
AMD   87.19 (+0.55%)
T   29.03 (+0.14%)
NIO   54.00 (+0.58%)
F   9.09 (+0.11%)
ACB   10.47 (+20.21%)
NFLX   491.36 (+1.31%)
GILD   60.03 (+0.89%)
BA   216.50 (-0.51%)
DIS   147.13 (-1.31%)
S&P 500   3,638.35 (+0.24%)
DOW   29,910.37 (+0.13%)
QQQ   299.01 (+0.92%)
AAPL   116.59 (+0.48%)
MSFT   215.23 (+0.64%)
FB   277.81 (+0.81%)
GOOGL   1,787.02 (+1.30%)
AMZN   3,195.34 (+0.32%)
TSLA   585.76 (+2.05%)
NVDA   530.45 (+0.20%)
BABA   276.48 (-0.45%)
CGC   29.00 (+7.93%)
GE   10.40 (-0.95%)
MU   64.23 (+1.26%)
AMD   87.19 (+0.55%)
T   29.03 (+0.14%)
NIO   54.00 (+0.58%)
F   9.09 (+0.11%)
ACB   10.47 (+20.21%)
NFLX   491.36 (+1.31%)
GILD   60.03 (+0.89%)
BA   216.50 (-0.51%)
DIS   147.13 (-1.31%)
Log in
NASDAQ:DTIL

Precision BioSciences Stock Forecast, Price & News

$11.93
+0.42 (+3.65 %)
(As of 11/27/2020 12:00 AM ET)
Add
Compare
Today's Range
$11.46
Now: $11.93
$12.02
50-Day Range
$6.15
MA: $7.86
$11.86
52-Week Range
$4.45
Now: $11.93
$23.67
Volume189,566 shs
Average Volume612,615 shs
Market Capitalization$626.09 million
P/E RatioN/A
Dividend YieldN/A
Beta1.1
Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company operates through two segments, Therapeutic and Food. It offers ARCUS, a genome-editing platform to cure cancers and genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities. This segment develops PBCAR0191, which is in Phase 1/2a clinical trial, an allogeneic CAR T cell therapy targeting the tumor target CD19 for acute lymphoblastic leukemia and non-hodgkin lymphoma; and PBCAR20A, an allogeneic anti-CD20 CAR T for the treatment NHL, chronic lymphocytic leukemia, and small lymphocytic lymphoma, as well as developing PBCAR269A, an allogeneic anti-BCMA CAR T cell product candidate for the treatment of R/R multiple myeloma. The Food segment develops food and nutrition products. The company has a development and commercial license agreement with Shire Plc for research and development of individual T cell modifications; and a collaboration agreement with Gilead Sciences, Inc. to co-develop a product candidate to cure chronic Hepatitis B infection. Precision BioSciences, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.53 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DTIL
CUSIPN/A
CIKN/A
Phone919-314-5512
Employees223

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$22.24 million
Book Value$1.22 per share

Profitability

Net Income$-92,880,000.00
Net Margins-484.81%

Miscellaneous

Market Cap$626.09 million
Next Earnings Date3/9/2021 (Estimated)
OptionableNot Optionable
$11.93
+0.42 (+3.65 %)
(As of 11/27/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive DTIL News and Ratings via Email

Sign-up to receive the latest news and ratings for DTIL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Precision BioSciences (NASDAQ:DTIL) Frequently Asked Questions

How has Precision BioSciences' stock been impacted by COVID-19 (Coronavirus)?

Precision BioSciences' stock was trading at $6.49 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, DTIL stock has increased by 83.8% and is now trading at $11.93.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Precision BioSciences?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Precision BioSciences in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Precision BioSciences
.

What stocks does MarketBeat like better than Precision BioSciences?

Wall Street analysts have given Precision BioSciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Precision BioSciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Precision BioSciences' next earnings date?

Precision BioSciences is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021.
View our earnings forecast for Precision BioSciences
.

How were Precision BioSciences' earnings last quarter?

Precision BioSciences, Inc. (NASDAQ:DTIL) announced its quarterly earnings results on Sunday, November, 15th. The company reported ($0.50) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.66) by $0.16. The business earned $7.36 million during the quarter, compared to analysts' expectations of $4.25 million. Precision BioSciences had a negative return on equity of 105.74% and a negative net margin of 484.81%.
View Precision BioSciences' earnings history
.

What price target have analysts set for DTIL?

5 brokers have issued 12 month price objectives for Precision BioSciences' stock. Their forecasts range from $18.00 to $22.00. On average, they anticipate Precision BioSciences' share price to reach $19.67 in the next twelve months. This suggests a possible upside of 64.9% from the stock's current price.
View analysts' price targets for Precision BioSciences
.

Who are some of Precision BioSciences' key competitors?

What other stocks do shareholders of Precision BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Precision BioSciences investors own include Editas Medicine (EDIT), Sorrento Therapeutics (SRNE), Alector (ALEC), Kaleido Biosciences (KLDO), Gossamer Bio (GOSS), Micron Technology (MU), Homology Medicines (FIXX), Heron Therapeutics (HRTX), Inovio Pharmaceuticals (INO) and Invitae (NVTA).

Who are Precision BioSciences' key executives?

Precision BioSciences' management team includes the following people:
  • Mr. Matthew R. Kane, Co-Founder, CEO, Pres & Director (Age 43, Pay $562.1k)
  • Mr. Dario Scimeca, Gen. Counsel & Sec. (Age 45, Pay $319.96k)
  • Dr. Christopher R. Heery, Chief Medical Officer (Age 40, Pay $444.03k)
  • Dr. Jefferson J. Smith Ph.D., Co-Founder & CTO
  • Mr. Abid Ansari, Chief Financial Officer (Age 42)
  • Dr. David S. Thomson Ph.D., Chief Operating Officer (Age 59)
  • Dr. Derek Jantz Ph.D., Co-Founder, Chief Scientific Officer & Director (Age 44)
  • Mr. Bruce Stevens, VP of Quality & Compliance
  • Ms. Heather King, Director of Marketing Communications & PR
  • Maurissa Messier, Sr. Director of Corp. Communications

When did Precision BioSciences IPO?

(DTIL) raised $126 million in an initial public offering (IPO) on Thursday, March 28th 2019. The company issued 7,900,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs, Jefferies and Barclays acted as the underwriters for the IPO.

What is Precision BioSciences' stock symbol?

Precision BioSciences trades on the NASDAQ under the ticker symbol "DTIL."

Who are Precision BioSciences' major shareholders?

Precision BioSciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.17%), ArrowMark Colorado Holdings LLC (4.62%), State Street Corp (1.48%), Principal Financial Group Inc. (0.71%), Adams Chetwood Wealth Management LLC (0.64%) and Charles Schwab Investment Management Inc. (0.55%). Company insiders that own Precision BioSciences stock include Christopher Heery, Global Strategic Fund Venbio and Tony Dung Ling Yao.
View institutional ownership trends for Precision BioSciences
.

Which institutional investors are selling Precision BioSciences stock?

DTIL stock was sold by a variety of institutional investors in the last quarter, including Adams Chetwood Wealth Management LLC, Cubist Systematic Strategies LLC, Thrivent Financial for Lutherans, Wells Fargo & Company MN, Morgan Stanley, Virtus ETF Advisers LLC, and Ironsides Asset Advisors LLC.
View insider buying and selling activity for Precision BioSciences
.

Which institutional investors are buying Precision BioSciences stock?

DTIL stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Point72 Asset Management L.P., ArrowMark Colorado Holdings LLC, Charles Schwab Investment Management Inc., GSA Capital Partners LLP, Moloney Securities Asset Management LLC, Squarepoint Ops LLC, and Quantitative Systematic Strategies LLC. Company insiders that have bought Precision BioSciences stock in the last two years include Christopher Heery, Global Strategic Fund Venbio, and Tony Dung Ling Yao.
View insider buying and selling activity for Precision BioSciences
.

How do I buy shares of Precision BioSciences?

Shares of DTIL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Precision BioSciences' stock price today?

One share of DTIL stock can currently be purchased for approximately $11.93.

How big of a company is Precision BioSciences?

Precision BioSciences has a market capitalization of $626.09 million and generates $22.24 million in revenue each year. The company earns $-92,880,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis. Precision BioSciences employs 223 workers across the globe.

What is Precision BioSciences' official website?

The official website for Precision BioSciences is www.precisionbiosciences.com.

How can I contact Precision BioSciences?

Precision BioSciences' mailing address is 302 EAST PETTIGREW STREET SUITE A-100, DURHAM NC, 27701. The company can be reached via phone at 919-314-5512 or via email at [email protected]

This page was last updated on 11/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.